For Q1 FY2026 ended March 31, 2026, Viking Therapeutics reported no revenue and a net loss of $158.3 million, a 247% increase from the prior year. Operating loss was $164.1 million, up 196% year-over-year. Diluted EPS was -$1.37, compared to -$0.41 a year ago. Cash and equivalents stood at $118.1 million, with total equity of $501.9 million.
•No revenue generated in Q1 FY2026.
•Net loss widened to $158.3 million from $45.6 million in Q1 FY2025.
•Operating loss increased to $164.1 million from $55.5 million.
•Cash position decreased to $118.1 million from $501.9 million in equity.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company develops novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery.
Its portfolio also includes VK0612, which is in Phase II clinical trials for metabolic disorders and anemia, and VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Incorporated in 2012, the company is headquartered in San Diego, California.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRβ), currently in Phase IIb clinical trials for treating patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and NAFLD. The company also has VK5211, an orally available non-steroidal selective androgen receptor modulator in Phase II trials for recovery from hip fracture surgery. Other pipeline assets include VK0612 for metabolic disorders and anemia, VK2735, a dual agonist of the glucagon-like peptide 1 in Phase 1 trials, and VK0214 for X-linked adrenoleukodystrophy. Viking Therapeutics is headquartered in San Diego, California.
Where is Viking Therapeutics (VKTX) listed and in which currency?
Viking Therapeutics (ticker symbol VKTX) is listed on the Nasdaq Capital Market (NasdaqCM) in the United States. Its shares are traded in US dollars (USD), which is the official currency of the United States. The NasdaqCM is a stock exchange that focuses on smaller, early-stage companies, and Viking Therapeutics, being a clinical-stage biopharmaceutical firm, fits this profile. Investors can buy and sell VKTX shares during regular trading hours on the NasdaqCM, and the stock price is quoted in USD.
What sector and industry does Viking Therapeutics (VKTX) belong to?
Viking Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes and living organisms to develop products and therapies, often for medical applications. As a clinical-stage biopharmaceutical company, Viking focuses on discovering and developing novel treatments for metabolic and endocrine disorders, such as NASH, NAFLD, and conditions related to hormone signaling. The biotechnology industry is known for high research and development costs, long development timelines, and significant regulatory hurdles, but also for the potential to address unmet medical needs.
Where is Viking Therapeutics (VKTX) headquartered and what markets does it serve?
Viking Therapeutics is headquartered in San Diego, California, United States. The company primarily serves the US market, as it is a US-based biopharmaceutical firm. Its clinical trials for drug candidates like VK2809, VK5211, and VK2735 are conducted in the United States, targeting patients with metabolic and endocrine disorders. While the company's focus is on developing therapies for global health issues such as NASH and NAFLD, its operations and regulatory filings are centered in the US. The company was incorporated in 2012 and has since been advancing its pipeline through clinical development.
What are the key drug candidates in Viking Therapeutics' (VKTX) pipeline?
Viking Therapeutics has a pipeline of drug candidates targeting metabolic and endocrine disorders. The lead candidate is VK2809, an orally available TRβ agonist in Phase IIb trials for NASH and NAFLD. VK5211, a non-steroidal selective androgen receptor modulator, is in Phase II for recovery from hip fracture surgery. VK0612 is in Phase II for metabolic disorders and anemia. VK2735, a dual GLP-1 agonist, is in Phase 1 single and multiple ascending dose trials. VK0214, another TRβ agonist, is being developed for X-linked adrenoleukodystrophy. These candidates represent the company's focus on oral, tissue-selective therapies with potential for treating significant unmet medical needs.